USA flag logo/image

An Official Website of the United States Government

Laser Device Development and Qualification to Enable Laser Tissue Welding

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96100
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
EB012371
Solicitation Year:
N/A
Solicitation Topic Code:
NIBIB
Solicitation Number:
N/A
Small Business Information
VISOTEK, INC.
11700 Belden Court Livonia, MI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Laser Device Development and Qualification to Enable Laser Tissue Welding
Agency: HHS
Contract: 1R43EB012371-01A1
Award Amount: $175,785.00
 

Abstract:

VISOTEK, Inc. is an OEM focusing its RandD and product development on novel diode lasers, systems and components that simplify the use of lasers in commercial, military, medical and research environments. Visotek proposes the development of an improved pa ssively cooled, compact, portable and cost effective 75 Watt, 808nm prototype laser for use in a surgical device developed by Laser Tissue Welding (LTW) , Inc. The laser, in combination with LTW's biomaterials, will provide quick and accurate hemostasis an d biliary sealing after liver resection surgery or hepatectomy for benign/primary/secondary liver neoplasms. The specific aim of the work is to demonstrate the feasibility of a prototype surgical laser system and handheld beam delivery optics to enable la ser tissue welding for liver repair. In Phase I, Visotek will develop an air cooled. compact, portable and cost effective 75 Watt near-infrared 808 5nm diode laser, with handheld beam delivery optics to deliver the required laser irradiance of 75-150W/cm [2] and fluence of 70-90 J/cm[2] with an 8mm spot size on a tophat beam profile that will efficiently and effectively coagulate albumin-indocyanine green solder used in the LTW process. The technological innovation of the resulting prototype delivered at the end of the Phase I effort is a wavelength stabilized laser system that incorporates passive cooling of the diodes at the required power levels without the use of an external water source or complicated cooling devices. Further innovation is in the dev elopment of a prototype handheld optical beam delivery system. In Phase II, Visotek will refine, optimize and validate the laser system and optics. The system weight will be reduced to 10kg., safety critical software will be developed. Laser Tissue Weld ing is an enhanced surgical capability with a new paradigm. Special areas of unmet clinical need are rapid hemostasis of solid visceral organs (liver/kidney/spleen) involved in trauma, tumors and transplantation and specifically in patients with coagulatio n failure or therapeutic anticoagulation. Currently the market is dominated by ablative technologies which create coagulative necrosis of gt1cm of normal liver tissues to obtain a hemostatic and biliary seal. Market size is 624,464 patients for liver surg ery alone. Market segments yearly growth trends are positive (liver transplant: 11%; cancer: 3% and trauma: 13%). The Company expects to serve 5% or ~31,223 patients in the 1st yr of market penetration (2012) and 30% year over year growth rate. Visotek is an established supplier of customized diode lasers and peripheral components and will become an OEM supplier to Laser Tissue Welding, Inc. for supply of complete LTW systems. Future variants will address other high power medical laser needs.

Principal Investigator:

Craig Lennon
7344274800
CLENNON@VISOTEKINC.COM

Business Contact:

Sheila Jensen
sjensen@visotekinc.com
Small Business Information at Submission:

VISOTEK, INC.
11700 BELDEN COURT LIVONIA, MI 48150

EIN/Tax ID: 138357867
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No